Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

The SNIPRx-surf platform is designed to detect cell surface targets in tumours or cancer models, utilising gene expression, ...

4D Molecular Therapeutics (4DMT) has received regenerative medicine advanced therapy (RMAT) designation from the US Food and ...

The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

Though optimistic, speakers at the recent LSX World Congress in London, UK, recognised that recent turbulence in the wake of ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.